CDC alters recommendations on rifamycin-antiretroviral drug use.
Miller
J L
JL
D000904:Antibiotics, Antitubercular / Q000009:adverse effects*; D002487:Centers for Disease Control and Prevention, U.S.; D004347:Drug Interactions; D006801:Humans; D017410:Practice Guidelines as Topic; D011480:Protease Inhibitors / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D017828:Rifabutin / Q000009:adverse effects; D012293:Rifampin / Q000009:adverse effects*; D014481:United States
D000904:Antibiotics, Antitubercular; D011480:Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D017828:Rifabutin; D012293:Rifampin